Sign in

CIK 0001841387

  • Emerging growth company

Candel Therapeutics, Inc.

Sign in to watch
Ticker
CADL
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
522214851
Phone
+1 617-916-5445
Business address
117 KENDRICK STREET, SUITE 450, NEEDHAM, MA, 02494
  1. 4 Open-market sale Chief Technology Officer sold 13,330 shares at $5.97 ($79,625)
  2. 4 Open-market sale Chief Executive Officer sold 20,293 shares at $5.97 ($121,218)
  3. 4 Open-market sale See Remarks sold 8,897 shares at $5.97 ($53,145)
  4. 4 Open-market sale Chief Medical Officer sold 9,769 shares at $5.97 ($58,354)
  5. 4 Open-market sale Chief Scientific Officer sold 12,645 shares at $5.97 ($75,534)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 3 Insider Initial Statement of Ownership
  15. 4 Shares withheld for taxes Chief Technology Officer gave up 17,328 shares (to pay taxes)
  16. 4 Shares withheld for taxes Chief Executive Officer gave up 43,443 shares (to pay taxes)
  17. 4 Shares withheld for taxes Chief Medical Officer gave up 12,175 shares (to pay taxes)
  18. 4 Shares withheld for taxes Chief Scientific Officer gave up 19,748 shares (to pay taxes)
  19. 4 Shares withheld for taxes Chief Financial Officer gave up 20,153 shares (to pay taxes)
  20. 4 Grant or award Chief Executive Officer acquired 180,108 shares (grant or award)

Page 6 of 11 · 202 filings